Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Chugai Pharmaceutical Co's average EPS without NRIGrowth Rate was 19.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 12.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 13.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 25.80% per year.
During the past 13 years, Chugai Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 47.70% per year. The lowest was -17.40% per year. And the median was 11.55% per year.
Chugai Pharmaceutical Co (OTCPK:CHGCF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Chugai Pharmaceutical Co Earnings per Share (Diluted) Related Terms
Chugai Pharmaceutical Co Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Chugai Pharmaceutical Co's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Earnings per Share (Diluted) Chart
CHGCF vs LLY, JNJ, ABBV: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's PE Ratio falls into.
Chugai Pharmaceutical Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Chugai Pharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $1.84 mean?
Chugai Pharmaceutical Co (CHGCF) has a Earnings per Share (Diluted) of $1.84 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Chugai Pharmaceutical Co and its competitors. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #352 out of 786 companies in the Drug Manufacturers industry, placing it in the top 44.8%.
Is Chugai Pharmaceutical Co's Earnings per Share (Diluted) too high?
Chugai Pharmaceutical Co's current Earnings per Share (Diluted) is $1.84. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.90. Chugai Pharmaceutical Co's value of $1.84 is 81.4% below this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #352 out of 786 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Earnings per Share (Diluted) compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #352 out of 786 companies for Earnings per Share (Diluted). This puts Chugai Pharmaceutical Co in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.90. Chugai Pharmaceutical Co's value of $1.84 is 81.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.90, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Earnings per Share (Diluted) of $1.84 is 81.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Earnings per Share (Diluted) is $1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Fairly Valued. The stock's GF Value™ is $47.40, compared to a current price of $43.78 — trading 7.6% below its estimated fair value. The current Earnings per Share (Diluted) is $1.84 and 81.4% below the Drug Manufacturers industry median of 9.90. Chugai Pharmaceutical Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Earnings per Share (Diluted) is $1.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $43.78 is trading 7.6% below its estimated GF Value™ of $47.40.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCF:
Earnings per Share (Diluted): $1.84
GF Value™: $47.40 vs. price of $43.78 (7.6% below fair value)
Industry Position: 81.4% below the Drug Manufacturers median (#352 of 786)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
89GF Score
Get the complete analysis for CHGCF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
